26 related articles for article (PubMed ID: 9719602)
1. Blocking potential metabolic sites on NAT to improve its safety profile while retaining the pharmacological profile.
Flammia R; Huang B; Pagare PP; M St Onge C; Abebayehu A; Gillespie JC; Mendez RE; Selley DE; Dewey WL; Zhang Y
Bioorg Chem; 2024 Jul; 148():107489. PubMed ID: 38797065
[TBL] [Abstract][Full Text] [Related]
2. A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates.
Ding H; Czoty PW; Kiguchi N; Cami-Kobeci G; Sukhtankar DD; Nader MA; Husbands SM; Ko MC
Proc Natl Acad Sci U S A; 2016 Sep; 113(37):E5511-8. PubMed ID: 27573832
[TBL] [Abstract][Full Text] [Related]
3. Opioid receptor selectivity profile change via isosterism for 14-O-substituted naltrexone derivatives.
Zhang Y; Elbegdorj O; Yuan Y; Beletskaya IO; Selley DE
Bioorg Med Chem Lett; 2013 Jul; 23(13):3719-22. PubMed ID: 23721804
[TBL] [Abstract][Full Text] [Related]
4. Most recent developments and modifications of 14-alkylamino and 14-alkoxy-4,5-epoxymorphinan derivatives.
Stavitskaya L; Coop A
Mini Rev Med Chem; 2011 Oct; 11(12):1002-8. PubMed ID: 21861811
[TBL] [Abstract][Full Text] [Related]
5. Activities of mixed NOP and mu-opioid receptor ligands.
Spagnolo B; Calo G; Polgar WE; Jiang F; Olsen CM; Berzetei-Gurske I; Khroyan TV; Husbands SM; Lewis JW; Toll L; Zaveri NT
Br J Pharmacol; 2008 Feb; 153(3):609-19. PubMed ID: 18059322
[TBL] [Abstract][Full Text] [Related]
6. Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorphinones and codeinones.
Nieland NP; Moynihan HA; Carrington S; Broadbear J; Woods JH; Traynor JR; Husbands SM; Lewis JW
J Med Chem; 2006 Aug; 49(17):5333-8. PubMed ID: 16913723
[TBL] [Abstract][Full Text] [Related]
7. Methoclocinnamox: a mu partial agonist with pharmacotherapeutic potential for heroin abuse.
Woods JH; Lewis JW; Winger G; Butelman E; Broadbear J; Zernig G
NIDA Res Monogr; 1995; 147():195-219. PubMed ID: 8742788
[No Abstract] [Full Text] [Related]
8. Opium alkaloids and affinity labels.
Archer S; Bidlack J; Mulholland GK
NIDA Res Monogr; 1990; 96():21-34. PubMed ID: 2172823
[No Abstract] [Full Text] [Related]
9. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
[TBL] [Abstract][Full Text] [Related]
10. Methoclocinnamox: agonist and antagonist effects of a novel long-lasting opioid in rhesus monkeys.
Butelman ER; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1996 Nov; 279(2):934-8. PubMed ID: 8930202
[TBL] [Abstract][Full Text] [Related]
11. Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity.
McLaughlin JP; Hill KP; Jiang Q; Sebastian A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1999 Apr; 289(1):304-11. PubMed ID: 10087018
[TBL] [Abstract][Full Text] [Related]
12. In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox.
Zernig G; Butelman ER; Lewis JW; Walker EA; Woods JH
J Pharmacol Exp Ther; 1994 Apr; 269(1):57-65. PubMed ID: 8169852
[TBL] [Abstract][Full Text] [Related]
13. Clocinnamox antagonism of the antinociceptive effects of mu opioids in squirrel monkeys.
Pitts RC; Allen RM; Walker EA; Dykstra LA
J Pharmacol Exp Ther; 1998 Jun; 285(3):1197-206. PubMed ID: 9618423
[TBL] [Abstract][Full Text] [Related]
14. 3-Alkyl ethers of clocinnamox: delayed long-term mu-antagonists with variable mu efficacy.
Husbands SM; Sadd J; Broadbear JH; Woods JH; Martin J; Traynor JR; Aceto MD; Bowman ER; Harris LS; Lewis JW
J Med Chem; 1998 Aug; 41(18):3493-8. PubMed ID: 9719602
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
